BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25955465)

  • 21. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
    Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J
    Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone.
    Dugan JP; Haverkos BM; Villagomez L; Martin LK; Lustberg M; Patton J; Martin M; Huang Y; Nuovo G; Yan F; Cavaliere R; Fingeroth J; Kenney SC; Ambinder RF; Lozanski G; Porcu P; Caligiuri MA; Baiocchi RA
    Clin Cancer Res; 2018 Jul; 24(14):3273-3281. PubMed ID: 29632007
    [No Abstract]   [Full Text] [Related]  

  • 23. Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients.
    Manlhiot C; Pollock-Barziv SM; Holmes C; Weitzman S; Allen U; Clarizia NA; Ngan BY; McCrindle BW; Dipchand AI
    J Heart Lung Transplant; 2010 Jun; 29(6):648-57. PubMed ID: 20304682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Post-transplant lymphoproliferative disorder: the significance of central nervous system disease.
    Araya CE
    Pediatr Transplant; 2012 Sep; 16(6):528-9. PubMed ID: 22717024
    [No Abstract]   [Full Text] [Related]  

  • 25. Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry.
    Zimmermann H; Nitsche M; Pott C; Reinke P; Babel N; Hermann RM; Hauser IA; Hahn D; Ritgen M; Pietschmann C; Klapper W; Anagnostopoulos I; Trappe RU;
    Ann Hematol; 2021 Aug; 100(8):2043-2050. PubMed ID: 33973053
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder Registry.
    Zimmermann H; Oschlies I; Fink S; Pott C; Neumayer HH; Lehmkuhl H; Hauser IA; Dreyling M; Kneba M; Gärtner B; Anagnostopoulos I; Riess H; Klapper W; Trappe RU
    Transplantation; 2012 Mar; 93(5):543-50. PubMed ID: 22234349
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Posttransplantation lymphoproliferative disorder: manifestations in pediatric thoracic organ recipients.
    Lim GY; Newman B; Kurland G; Webber SA
    Radiology; 2002 Mar; 222(3):699-708. PubMed ID: 11867788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary Central Nervous System Post-transplant Lymphoproliferative Disorder Misdiagnosed as Glioblastoma: A Case Report.
    Tanaka H; Matsuda R; Nakamura M; Nakagawa I; Nakase H
    Anticancer Res; 2022 Aug; 42(8):3975-3979. PubMed ID: 35896237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Posttransplant lymphoproliferative disorder in pediatric renal transplantation.
    Srivastava T; Zwick DL; Rothberg PG; Warady BA
    Pediatr Nephrol; 1999 Nov; 13(9):748-54. PubMed ID: 10603113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage.
    Crane GM; Powell H; Kostadinov R; Rocafort PT; Rifkin DE; Burger PC; Ambinder RF; Swinnen LJ; Borowitz MJ; Duffield AS
    Oncotarget; 2015 Oct; 6(32):33849-66. PubMed ID: 26460822
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations.
    Walker RC; Paya CV; Marshall WF; Strickler JG; Wiesner RH; Velosa JA; Habermann TM; Daly RC; McGregor CG
    J Heart Lung Transplant; 1995; 14(2):214-21. PubMed ID: 7779838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy.
    Gulley ML; Swinnen LJ; Plaisance KT; Schnell C; Grogan TM; Schneider BG;
    Transplantation; 2003 Sep; 76(6):959-64. PubMed ID: 14508361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Post-transplant lymphoproliferative disorders of oral cavity.
    Ojha J; Islam N; Cohen DM; Marshal D; Reavis MR; Bhattacharyya I
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 May; 105(5):589-96. PubMed ID: 18442744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Posttransplant lymphoproliferative disorder after liver and kidney transplant.
    Akar Özkan E; Özdemir BH; Deniz EE; Tunca MZ; Haberal M
    Exp Clin Transplant; 2014 Mar; 12 Suppl 1():142-8. PubMed ID: 24635813
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation.
    Maecker B; Jack T; Zimmermann M; Abdul-Khaliq H; Burdelski M; Fuchs A; Hoyer P; Koepf S; Kraemer U; Laube GF; Müller-Wiefel DE; Netz H; Pohl M; Toenshoff B; Wagner HJ; Wallot M; Welte K; Melter M; Offner G; Klein C
    J Clin Oncol; 2007 Nov; 25(31):4902-8. PubMed ID: 17971586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two cases of post transplant lymphoproliferative disorder in lung transplant recipients.
    Chang YS; Kim Y; Kim DY; Kim HJ; Ahn CM; Lee DY; Paik HC
    Korean J Intern Med; 2004 Dec; 19(4):276-81. PubMed ID: 15683119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identifying predictive factors for posttransplant lymphoproliferative disease in pediatric solid organ transplant recipients with Epstein-Barr virus viremia.
    Weintraub L; Weiner C; Miloh T; Tomaino J; Joashi U; Benchimol C; Strauchen J; Roth M; Wistinghausen B
    J Pediatr Hematol Oncol; 2014 Nov; 36(8):e481-6. PubMed ID: 24878618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Airway plaque presenting after alteration of immunosuppression in a pediatric patient remote from heart transplantation.
    Ryan TD; Absalon MJ; de Alarcon A; Gupta A; Peters AL; Lorts A; Danziger-Isakov LA; Chin C
    Pediatr Transplant; 2017 Nov; 21(7):. PubMed ID: 28836710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thoracic presentations of posttransplant lymphoproliferative disorders.
    Halkos ME; Miller JI; Mann KP; Miller DL; Gal AA
    Chest; 2004 Dec; 126(6):2013-20. PubMed ID: 15596707
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Posttransplant lymphoproliferative disorders in transplant recipients.
    Timurağaoğlu A; Uğur-Bilgin A; Colak D; Tuncer M; Gölbaşi I; Hazar V; Kiliçarsłan B; Undar L; Demirbaş A
    Transplant Proc; 2006 Mar; 38(2):641-5. PubMed ID: 16549195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.